Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801642 · ClinicalTrials.gov registry record · Phase 1
Dapagliflozin In Alzheimer's Disease
A Phase 1 study, sponsored by Jeff Burns, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT03801642: Completed Phase 1 study, sponsored by Jeff Burns, MD.
NCT03801642 is a Phase 1 study that has completed, run by Jeff Burns, MD. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03801642, a Phase 1 study, has completed, sponsored by Jeff Burns, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl aspartate (NAA) levels using magnetic resonance spectroscopy (MRS). The investigators will also examine the safety and tolerability of dapagliflozin and explore the effects on systemic NAA levels in blood and urine, cerebral metabolism (fluorodeoxyglucose \[FDG\] PET), systemic metabolic biomarkers that indicate and quantify secondary metabolic effects, and cognitive performance.
Interventions
- OTHER Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03801642
The ClinicalTrials.gov registry entry for NCT03801642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeff Burns, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03801642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03801642 about?
NCT03801642 is a clinical study titled "Dapagliflozin In Alzheimer's Disease". This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl aspartate (NAA) levels using magnetic resonance spectroscopy (MRS). The investigators will also examine the safety a...
What is the current status of trial NCT03801642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2019-01-29. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT03801642?
The interventions under investigation include: Placebo (OTHER), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03801642?
This trial is sponsored by Jeff Burns, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.